Skip to main content
. 2019 Oct 22;63(11):e01154-19. doi: 10.1128/AAC.01154-19

TABLE 2.

Activity of minocycline and comparators when tested against Acinetobacter baumannii-Acinetobacter calcoaceticus species complex, Stenotrophomonas maltophilia, and Burkholderia cepacia complex isolates from the United States (2014 to 2018)

Organism/organism group (no. of isolates) and antimicrobial agent MIC50 (μg/ml) MIC90 (μg/ml) Range (μg/ml) CLSIa
%S %I %R
A. baumannii-A. calcoaceticus complex (1,081)
    Amikacin 4 >32 ≤0.25–>32 79.2 2.6 18.2
    Ampicillin-sulbactam 4 >32 0.5–32 62.4 12.9 24.7
    Cefepime 8 >16 ≤0.5–>16 50.8 11.5 37.7
    Ceftazidime 8 >32 0.5–>32 56.0 6.2 37.8
    Colistin ≤0.5 2 ≤0.5–>8 92.4 7.6
    Gentamicin ≤1 >8 ≤1–>8 64.0 5.1 30.9
    Imipenem 0.25 >8 ≤0.12–>8 61.5 3.2 35.2
    Levofloxacin 0.5 >4 ≤0.12–>4 55.2 1.9 42.9
    Meropenem 1 >32 0.06–>32 58.8 1.9 39.4
    Minocycline 0.25 8 ≤0.06–>8 85.7 6.1 8.2
    Piperacillin-tazobactam 16 >64 ≤0.5–>64 50.2 7.6 42.1
    Tetracyclineb 4 >8 ≤0.5–>8 51.8 6.1 42.1
    Trimethoprim-sulfamethoxazole ≤0.5 >4 ≤0.5–>4 59.6 40.4
MDR A. baumannii-A. calcoaceticus complex (539)c
    Amikacin 8 >32 0.5–>32 58.7 5.0 36.3
    Ampicillin-sulbactam 16 >32 1–>32 25.8 24.9 49.4
    Cefepime >16 >16 2–>16 7.8 18.4 73.8
    Ceftazidime >32 >32 2–>32 16.5 9.8 73.7
    Colistin ≤0.5 4 ≤0.5–>8 87.9 12.1
    Gentamicin >8 >8 ≤1–>8 30.1 9.3 60.7
    Imipenem >8 >8 ≤0.12–>8 22.8 6.5 70.7
    Levofloxacin >4 >4 ≤0.12–>4 11.3 3.3 85.3
    Meropenem 32 >32 0.12–>32 18.0 3.2 78.8
    Minocycline 2 >8 ≤0.06–>8 71.2 12.2 16.5
    Piperacillin-tazobactam >64 >64 ≤0.5–>64 7.1 12.8 80.1
    Tetracyclineb >8 >8 ≤0.25–>8 10.2 8.2 81.6
    Trimethoprim-sulfamethoxazole >4 >4 ≤0.5–>4 25.0 75.0
XDR A. baumannii-A. calcoaceticus (401)c
    Amikacin 32 >32 0.5–>32 48.9 6.0 45.1
    Ampicillin-sulbactam 32 >32 2–>32 11.2 28.7 60.1
    Cefepime >16 >16 4–>16 2.5 15.2 82.3
    Ceftazidime >32 >32 2–>32 11.0 8.0 81.0
    Colistin ≤0.5 4 ≤0.5–>8 86.5 13.5
    Gentamicin >8 >8 ≤1–>8 18.0 9.5 72.6
    Imipenem >8 >8 0.25– >8 6.7 5.2 88.0
    Levofloxacin >4 >4 0.5–>4 1.2 3.0 95.8
    Meropenem >32 >32 1–>32 2.5 3.5 94.0
    Minocycline 2 >8 0.06–>8 67.3 13.7 19.0
    Piperacillin-tazobactam >64 >64 8–>64 0.2 6.2 93.5
    Tetracyclineb >8 >8 1–>8 3.4 6.2 90.5
    Trimethoprim-sulfamethoxazole >4 >4 ≤0.5–>4 14.2 85.8
S. maltophilia (1,289)
    Amikacin >32 >32 1–>32
    Ampicillin-sulbactam >32 >32 2>32
    Cefepime >16 >16 ≤0.5–>16
    Ceftazidime 32 >32 0.5–>32 26.8 9.9 63.3
    Colistin 4 >8 ≤0.5–>8
    Gentamicin >8 >8 ≤1–>8
    Imipenem >8 >8 0.5–>8
    Levofloxacin 1 >4 ≤0.12–>4 75.8 9.7 14.5
    Meropenem >32 >32 0.03–>32
    Minocycline 0.5 2 ≤0.06–>8 99.5 0.2 0.2
    Piperacillin-tazobactam >64 >64 2–>64
    Tetracyclineb >8 >8 0.5–>8
    Trimethoprim-sulfamethoxazole ≤0.5 1 ≤0.5–>4 94.6 5.4
Trimethoprim-sulfamethoxazole-resistant S. maltophilia (69)
    Ceftazidime >32 >32 1–>32 20.3 4.3 75.4
    Levofloxacin >4 >4 0.5–>4 21.7 15.9 62.3
    Minocycline 1 4 0.12–>8 92.8 4.3 2.9
B. cepacia complex (101)
    Amikacin >32 >32 ≤0.25–>32
    Ampicillin-sulbactam >32 >32 1–>32
    Cefepime 16 >16 ≤0.5–>16
    Ceftazidime 2 8 0.5–>32 91.0 4.0 5.0
    Colistin >8 >8 ≤0.5–8
    Gentamicin >8 >8 ≤0.5–>8
    Imipenem 4 >8 ≤0.12–>8
    Levofloxacin 2 >4 ≤0.12–>4 71.3 9.9 18.8
    Meropenem 2 8 0.06–>32 89.1 5.0 5.9
    Minocycline 2 8 ≤0.06–>8 88.1 6.9 5.0
    Piperacillin-tazobactam 4 64 ≤0.5–>64
    Tetracyclineb >8 >8 2–>8
    Trimethoprim-sulfamethoxazole ≤0.5 2 ≤0.5–>4 93.1 6.9
a

Clinical and Laboratory Standards Institute (2019). S, susceptible; I, intermediate; R, resistant.

b

Not tested in 2015.

c

Multidrug-resistant and extensively drug-resistant as described in references 7 and 28.